| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology | 254 | GlobeNewswire (Europe) | NEW YORK, April 11, 2024) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, "Treatment... ► Artikel lesen | |
| Do | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 05.03. | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease | 640 | GlobeNewswire (Europe) | Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD) and Parkinson's disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that occurs... ► Artikel lesen | |
| 05.03. | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 08.01. | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients | 392 | GlobeNewswire (Europe) | NEW YORK, Jan. 08, 2024) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of... ► Artikel lesen | |
| 08.01. | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 05.01. | Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 | 818 | GlobeNewswire (Europe) | NEW YORK, Jan. 05, 2024) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical... ► Artikel lesen | |
| 05.01. | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation | 297 | GlobeNewswire (Europe) | NEW YORK, Jan. 05, 2024) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition... ► Artikel lesen | |
| 29.12.23 | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 19.12.23 | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis | 311 | GlobeNewswire (Europe) | NEW YORK, Dec. 19, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced "first patient dosed" in its Phase 2a study comparing... ► Artikel lesen | |
| 19.12.23 | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 04.12.23 | Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar | 420 | GlobeNewswire (Europe) | NEW YORK, Dec. 04, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis... ► Artikel lesen | |
| 30.11.23 | Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis | 312 | GlobeNewswire (Europe) | NEW YORK, Nov. 30, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company... ► Artikel lesen | |
| 30.11.23 | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.11.23 | Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 | 459 | GlobeNewswire (Europe) | NEW YORK, Nov. 01, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating... ► Artikel lesen | |
| 01.11.23 | Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 5.232 |
| VARTA | 4.728 |
| RHEINMETALL | 2.925 |
| RENK GROUP | 2.559 |
| NEL | 2.437 |
| BAYER | 2.426 |
| NVIDIA | 2.308 |
| DEUTSCHE LUFTHANSA | 2.187 |
| BARRICK GOLD | 1.838 |
| BYD | 1.814 |
| TESLA | 1.810 |
| DEUTSCHE BANK | 1.416 |
| AIXTRON SE | 1.414 |
| DEUTSCHE TELEKOM | 1.272 |
| BASF | 1.267 |
| MERCEDES-BENZ | 1.190 |
| EVOTEC | 1.170 |
| THYSSENKRUPP | 1.146 |
| ALLIANZ | 1.063 |
| RWE | 1.061 |
| PLUG POWER | 1.049 |
| VOLKSWAGEN | 1.030 |
| COMMERZBANK | 977 |
| SUPER MICRO COMPUTER | 938 |
| SIEMENS ENERGY | 896 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
